263 results on '"Carrato, Cristina"'
Search Results
2. Contributors
3. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
4. Data mining analyses for precision medicine in acromegaly: a proof of concept
5. New molecular tools for precision medicine in pituitary neuroendocrine tumors.
6. The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation
7. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
8. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
9. Intimal disruption in type B aortic intramural hematoma. Does size matter? A systematic review and meta-analysis
10. Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
11. Usefulness of the short version of the acute octreotide test for prediction of first-generation somatostatin receptor ligands response in acromegaly: a validation study with the ACROFAST cohort
12. Supplementary Data files S1 a_f from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
13. Supplementary Fig. S4 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
14. Supplementary Table S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
15. Table S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
16. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors
17. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
18. Supplementary Information to Gal-1 expression analysis in the GLIOCAT multicenter study: role as a prognostic factor and an immune-suppressive biomarker
19. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
20. Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
21. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas
22. Chapter 4 - Forging a path to the use of liquid biopsy in the diagnosis of gliomas
23. Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood
24. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
25. Is IDO1 an adequate target for treatment in glioblastoma?
26. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification
27. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response
28. Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
29. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response
30. Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy
31. Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment
32. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation
33. MP60-20 DETECTION OF LYMPH NODE METASTASES USING POOLING METHOD BY ONE-STEP NUCLEIC ACID AMPLIFICATION (OSNA) ASSAY IN PROSTATE CANCER PATIENTS: PRELIMINARY RESULTS FROM A PROSPECTIVE-MULTICENTRE STUDY
34. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients
35. Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease
36. Gene fusions in glioblastoma: Results of Gliocat project.
37. Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.
38. The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals
39. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases
40. Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy
41. Immunohistochemistry-based taxonomical classification of Bladder cancer predicts response to neoadjuvant chemotherapy
42. Cervical Follicular Dendritic-Cell Sarcoma
43. RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP–negative Glioblastoma
44. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
45. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours
46. Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome
47. Complete Loss of EPCAM Immunoexpression Identifies EPCAM Deletion Carriers in MSH2-Negative Colorectal Neoplasia
48. Reply to: “Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?”
49. Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
50. Data mining analyses for precision medicine in acromegaly
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.